Zenghua Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zenghua Lin has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Chenyan Lu
Department of Hypoxic Biomedicine, Institute of Special Environmental Medicine, Nantong University, Nantong 226001, China
1 shared publication Chunfeng Sun
Department of Nuclear Medicine, Affiliated Hospital of Nantong University
1 shared publication- Guohua Wang
Department of Neurology, Xuanwu Hospital, Capital Medical University , Beijing
1 shared publication - Jiali Hua
Department of Hypoxic Biomedicine, Institute of Special Environmental Medicine, Nantong University, Nantong 226001, China
1 shared publication - Jiawei Liu
Department of Hypoxic Biomedicine, Institute of Special Environmental Medicine, Nantong University, Nantong 226001, China
1 shared publication Jiawen Jiang
Department of Hematology, Medical School of Nantong University
1 shared publication
Latest Publications
- Open Access
- 20 September 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (9) , 1205
Shengmai Yin Attenuates Hypobaric Hypoxia-Induced Erythrocyte Echinocytosis by Restoring Redox Homeostasis and Normalizing Band 3–Syk/SHP2 Interactions
Acute exposure to high-altitude hypobaric hypoxia (HH) disrupts redox homeostasis and impairs erythrocyte morphology and oxygen transport. Shengmai Yin (SMY) is a botanical formulation with reported antioxidant activity, but its effects on HH-induced erythrocyte injury remain unclear. Male C57BL/6J mice received SMY in drinking water for 3 days before 24 h of simulated HH equivalent to 6000 m. Complementary in vivo and in vitro experiments assessed redox indices, lipid peroxidation, hemoglobin redox status, erythrocyte morphology, arterial oxygenation, and Band 3-associated protein interactions. HH increased serum DHE-derived fluorescence, nitric oxide, and malondialdehyde, reduced antioxidant capacity, induced echinocytosis, decreased oxyhemoglobin, and increased methemoglobin. Among the tested redox challenges, 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide (PTIO) most closely reproduced the combined morphological and hemoglobin abnormalities. SMY scavenged DPPH, hydroxyl-radical, and superoxide-related signals in cell-free assays; reduced PTIO- and hypoxia-induced erythrocyte damage; and reversed established echinocytosis within 30 min in vitro. In mice, SMY reduced echinocytosis and improved arterial oxygenation without detectable short-term hepatic, renal, or histological toxicity. SMY also normalized HH- and PTIO-induced changes in Band 3 interactions with Syk and SHP2. These findings support SMY as a redox-modulating intervention that preserves erythrocyte structure and function during acute HH.
- 20 September 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (9) , 1205
Open AccessShengmai Yin Attenuates Hypobaric Hypoxia-Induced Erythrocyte Echinocytosis by Restoring Redox Homeostasis and Normalizing Band 3–Syk/SHP2 Interactions
Acute exposure to high-altitude hypobaric hypoxia (HH) disrupts redox homeostasis and impairs erythrocyte morphology and oxygen transport. Shengmai Yin (SMY) is a botanical formulation with reported antioxidant activity, but its effects on HH-induced erythrocyte injury remain unclear. Male C57BL/6J mice received SMY in drinking water for 3 days before 24 h of simulated HH equivalent to 6000 m. Complementary in vivo and in vitro experiments assessed redox indices, lipid peroxidation, hemoglobin redox status, erythrocyte morphology, arterial oxygenation, and Band 3-associated protein interactions. HH increased serum DHE-derived fluorescence, nitric oxide, and malondialdehyde, reduced antioxidant capacity, induced echinocytosis, decreased oxyhemoglobin, and increased methemoglobin. Among the tested redox challenges, 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide (PTIO) most closely reproduced the combined morphological and hemoglobin abnormalities. SMY scavenged DPPH, hydroxyl-radical, and superoxide-related signals in cell-free assays; reduced PTIO- and hypoxia-induced erythrocyte damage; and reversed established echinocytosis within 30 min in vitro. In mice, SMY reduced echinocytosis and improved arterial oxygenation without detectable short-term hepatic, renal, or histological toxicity. SMY also normalized HH- and PTIO-induced changes in Band 3 interactions with Syk and SHP2. These findings support SMY as a redox-modulating intervention that preserves erythrocyte structure and function during acute HH.
- Open Access
- 17 February 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1724213
Case Report: Glofitamab in the treatment of a patient with central nervous system-involved Burkitt lymphoma
Burkitt lymphoma (BL) is a rare and highly aggressive B-cell non-Hodgkin lymphoma. While targeted combination chemotherapy can be effective, it is associated with a high rate of relapsed or refractory disease and a pronounced propensity for central nervous system (CNS) involvement. Currently, novel therapies such as chimeric antigen receptor T-cell (CAR-T) therapy have not demonstrated established efficacy in BL. Given the poor prognosis and the challenge of managing relapsed/refractory BL, the use of bispecific antibodies, specifically glofitamab, as employed in this case, has yielded a favorable therapeutic outcome. This is particularly noteworthy in the present case, given the patient’s documented CNS infiltration. After the failure of first-line treatment in this case, the combination of glofitamab and a Bruton’s tyrosine kinase inhibitor (BTKi) was used for six cycles, which significantly improved the patient’s CNS infiltration and achieved a long remission period. This provides an opportunity to try glofitamab in the treatment of CNS lymphoma, and we look forward to its confirmation in more BL patients.
- 17 February 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1724213
Open AccessCase Report: Glofitamab in the treatment of a patient with central nervous system-involved Burkitt lymphoma
Burkitt lymphoma (BL) is a rare and highly aggressive B-cell non-Hodgkin lymphoma. While targeted combination chemotherapy can be effective, it is associated with a high rate of relapsed or refractory disease and a pronounced propensity for central nervous system (CNS) involvement. Currently, novel therapies such as chimeric antigen receptor T-cell (CAR-T) therapy have not demonstrated established efficacy in BL. Given the poor prognosis and the challenge of managing relapsed/refractory BL, the use of bispecific antibodies, specifically glofitamab, as employed in this case, has yielded a favorable therapeutic outcome. This is particularly noteworthy in the present case, given the patient’s documented CNS infiltration. After the failure of first-line treatment in this case, the combination of glofitamab and a Bruton’s tyrosine kinase inhibitor (BTKi) was used for six cycles, which significantly improved the patient’s CNS infiltration and achieved a long remission period. This provides an opportunity to try glofitamab in the treatment of CNS lymphoma, and we look forward to its confirmation in more BL patients.